ReviewCancer management and research2014
New modalities of cancer treatment for NSCLC: focus on immunotherapy.
Review in Cancer management and research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06584435 (A Single-arm Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer), which is not on this map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-arm Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer
Who cites it
33 citing papers in PubMed, 78 citations in OpenAlex.
- Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials.Journal for immunotherapy of cancer · 2017Trial
- FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.The oncologist · 2016Trial
- Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.Advanced healthcare materials · 2024Review
- Chemotherapy: A partnership with immunotherapy in non-small cell lung cancer.Thoracic cancer · 2023Review
- The emerging nanomedicine-based technology for non-small cell lung cancer immunotherapy: how far are we from an effective treatment.Frontiers in oncology · 2023Review
- Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice.Cancers · 2022Review
- Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients.Medicina (Kaunas, Lithuania) · 2021Review
- Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets.International journal of molecular sciences · 2021Review
- Recent advances of the regulation roles of MicroRNA in glioblastoma.International journal of clinical oncology · 2020Review
- Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy.Cancers · 2020Review
- Treatment Patterns and Costs Associated with Stage IV Non-Small Cell Lung Cancer in a Mexican Population: A Chart Review.PharmacoEconomics - open · 2020Article
- Article
- Manipulation of the immune system by non-small cell lung cancer and possible therapeutic interference.Cancer drug resistance (Alhambra, Calif.) · 2020Review
- Glucose Metabolism on Tumor Plasticity, Diagnosis, and Treatment.Frontiers in oncology · 2020Review
- Next-Generation Immunotherapies to Improve Anticancer Immunity.Frontiers in pharmacology · 2020Review
- Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects.Frontiers in oncology · 2020Review
- Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report.Lung cancer management · 2019Article
- Identifying pathological subtypes of non-small-cell lung cancer by using the radiomic features ofTranslational cancer research · 2019Article
- MALDI Mass Spectrometry Imaging Linked with Top-Down Proteomics as a Tool to Study the Non-Small-Cell Lung Cancer Tumor Microenvironment.Methods and protocols · 2019Article
- Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches.Frontiers in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in the understanding of immunology and antitumor immune responses have led to the development of new immunotherapies, including vaccination approaches and monoclonal antibodies that inhibit immune checkpoint pathways. These strategies have shown activity in melanoma and are now being tested in lung cancer. The antibody drugs targeting cytotoxic T-lymphocyte-associated antigen-4 and programmed cell death protein-1 immune checkpoint pathways work by restoring immune responses against cancer cells, and are associated with unconventional response patterns and immune-related adverse events as a result of their mechanism of action. As these new agents enter the clinic, nurses and other health care providers will require an understanding of the unique efficacy and safety profiles with immunotherapy to optimize potential patient benefits. This paper provides a review of the new immunotherapeutic agents in development for lung cancer, and strategies for managing patients on immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.